Patrick Lin, Chief Business - Strategy Officer at Processa Pharmaceuticals, Inc. (PCSA), bought 4,000 shares at $2.37 ($10K) on 2024-01-31, disclosed to the SEC on 2024-02-01.
Open-market purchase of $10k PCSA by Chief Business - Strategy Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.37 | 2,500 | $6K | 62.2% |
| 2 | $2.40 | 1,500 | $4K | 37.8% |
| Total | $2.38 avg | 4,000 | $10K | 100% |
| Filing → |
| PCSA | BUY | 2026-06-01 | $4K | — | Filing → |
| PCSA | BUY | 2026-05-19 | $4K | — | Filing → |
| PCSA | BUY | 2026-05-01 | $4K | — | Filing → |